{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:12:01Z","timestamp":1793416321805,"version":"4.5.0"},"reference-count":55,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["2024_EKEA.176 and 2025_EKMS.01"],"award-info":[{"award-number":["2024_EKEA.176 and 2025_EKMS.01"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["ref. 70115384"],"award-info":[{"award-number":["ref. 70115384"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predicting toxicity remain lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective, multicenter study, we analyzed pretreatment serum samples from 331 patients with metastatic melanoma treated with anti-CTLA-4 (ipilimumab), anti-PD-1 (pembrolizumab or nivolumab), or combination ipilimumab\/nivolumab. IgG autoantibody reactivity against 832 human protein antigens, including autoimmune targets, cytokines, tumor-associated antigens, and cancer pathway proteins, was profiled using multiplex bead-based arrays. Statistical analysis (Significance Analysis of Microarrays and Cox regression) identified autoantibody signatures associated with subsequent irAEs and immune-related colitis (ir-colitis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We detected 47 autoantibodies predictive of irAEs, with KRT7, RPLP2, UBE2Z, and GPHN emerging as the strongest markers. Anti-KRT7 and anti-GPHN were specifically predictive in patients receiving PD-1 monotherapy, whereas anti-RPLP2 was associated with irAEs in ipilimumab\/nivolumab combination therapy. For ir-colitis, 38 autoantibodies were identified, with five (PIAS3, RPLP0, UBE2Z, KRT7, and SDCBP) showing consistent predictive value across treatment groups. Anti-PIAS3 and anti-RPLP0 increased ir-colitis risk, while anti-SDCBP conferred protection. Notably, predictive profiles differed between PD-1-based and CTLA-4-based regimens, underscoring divergent mechanisms of toxicity. Several autoantibodies predictive of irAEs or ir-colitis also correlated with clinical outcome. ATG4D, MAGEB4, and IL4R were associated with prolonged progression-free and overall survival, whereas FGFR1 predicted both reduced irAE risk and inferior survival, consistent with the link between heightened immune activation, toxicity, and therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study, to our knowledge, is the largest pretreatment autoantibody screen in melanoma immunotherapy, demonstrates that serum autoantibody profiles can stratify patients at risk for irAEs and ir-colitis. The identified signatures connect tumor-related and immunity-related antigens, stress-response pathways, and autoimmune mechanisms. Pretreatment autoantibody profiling offers a promising biomarker-driven approach for individualizing risk assessment, improving patient selection, and guiding early intervention strategies to enhance the safety of immune checkpoint blockade in melanoma. Beyond toxicity prediction, our findings also suggest that specific autoantibodies may reflect underlying immune activation states linked to therapeutic response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013814","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:40:27Z","timestamp":1769528427000},"page":"e013814","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-2526","authenticated-orcid":false,"given":"Robin","family":"Reschke","sequence":"first","affiliation":[{"name":"Department of Dermatology, National Center for Tumor Diseases and German Cancer Consortium (DKTK), University Hospital Heidelberg and Medical Faculty, University Heidelberg, Heidelberg, Germany"},{"name":"CCU Applied Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Budde","sequence":"additional","affiliation":[{"name":"CSO, Oncimmune Germany GmbH, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Zucht","sequence":"additional","affiliation":[{"name":"Oncimmune Germany GmbH, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Zurich, University Hospital Zurich and Kantonsspital Aarau, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pfoehler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany, Homburg\/Saarland, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3104-8512","authenticated-orcid":false,"given":"Kilian","family":"Wistuba-Hamprecht","sequence":"additional","affiliation":[{"name":"Skin Cancer Unit and DKFZ-Hector Cancer Institute, German Cancer Research Center, Mannheim\/Heidelberg, Germany"},{"name":"Department of Dermatology, Venereology and Allergology, Mannheim Institute for Innate Immunoscience (MI3), University Medical Center and Medical Faculty Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weide","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara-Elena","family":"Hakim-Meibodi","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Richter","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manual","family":"Br\u00e4utigam","sequence":"additional","affiliation":[{"name":"Oncimmune Germany GmbH, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gutjahr","sequence":"additional","affiliation":[{"name":"Oncimmune, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schulz-Knappe","sequence":"additional","affiliation":[{"name":"Oncimmune, Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C","family":"Hassel","sequence":"additional","affiliation":[{"name":"Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology, and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026012707402071000_14.1.e013814.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026012707402071000_14.1.e013814.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.003"},{"key":"2026012707402071000_14.1.e013814.3","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"2026012707402071000_14.1.e013814.4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026012707402071000_14.1.e013814.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front Immunol"},{"key":"2026012707402071000_14.1.e013814.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.11.009"},{"key":"2026012707402071000_14.1.e013814.7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of Autoantibody-Induced Pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"2026012707402071000_14.1.e013814.8","doi-asserted-by":"crossref","first-page":"48507","DOI":"10.18632\/oncotarget.17397","article-title":"Implementing liquid biopsies into clinical decision making for cancer immunotherapy","volume":"8","author":"Quandt","year":"2017","journal-title":"Oncotarget"},{"key":"2026012707402071000_14.1.e013814.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026012707402071000_14.1.e013814.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008215","article-title":"Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer","volume":"12","author":"Ravi","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026012707402071000_14.1.e013814.11","first-page":"812","article-title":"Multiparametric detection of autoantibodies in systemic lupus erythematosus","volume":"25","author":"Budde","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"2026012707402071000_14.1.e013814.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.091062498"},{"key":"2026012707402071000_14.1.e013814.13","doi-asserted-by":"crossref","first-page":"10011","DOI":"10.1200\/JCO.2020.38.15_suppl.10011","article-title":"Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma","volume":"38","author":"Hassel","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026012707402071000_14.1.e013814.14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0362"},{"key":"2026012707402071000_14.1.e013814.15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamadermatol.2024.4445","article-title":"Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome","volume":"161","author":"Reschke","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026012707402071000_14.1.e013814.16","doi-asserted-by":"crossref","first-page":"115750","DOI":"10.1016\/j.ejca.2025.115750","article-title":"Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients","volume":"228","author":"Ugurel","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026012707402071000_14.1.e013814.17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1703481","article-title":"Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012707402071000_14.1.e013814.18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","article-title":"Targeting molecular pathways to control immune checkpoint inhibitor toxicities","volume":"46","author":"Reschke","year":"2025","journal-title":"Trends Immunol"},{"key":"2026012707402071000_14.1.e013814.19","doi-asserted-by":"crossref","unstructured":"Sasson SC , Slevin SM , Cheung VTF , et al . Oxford Inflammatory Bowel Disease Cohort Investigators. Gastroenterology 2021;161. doi:10.1053\/j.gastro.2021.06.025","DOI":"10.1053\/j.gastro.2021.06.025"},{"key":"2026012707402071000_14.1.e013814.20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2197358","article-title":"Tissue-resident memory T cells in immune-related adverse events: friend or foe?","volume":"12","author":"Reschke","year":"2023","journal-title":"Oncoimmunology"},{"key":"2026012707402071000_14.1.e013814.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1385781","article-title":"The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?","volume":"15","author":"Reschke","year":"2024","journal-title":"Front Immunol"},{"key":"2026012707402071000_14.1.e013814.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02205-y","article-title":"Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities","volume":"10","author":"Reschke","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026012707402071000_14.1.e013814.23","first-page":"638","article-title":"Anhaltende Remission eines metastasierten Melanoms unter zielgerichteter Therapie und Rituximab bei rheumatoider Arthritis","volume":"17","author":"Reschke","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026012707402071000_14.1.e013814.24","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001777"},{"key":"2026012707402071000_14.1.e013814.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009215","article-title":"Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma","volume":"12","author":"Borgers","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026012707402071000_14.1.e013814.26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026012707402071000_14.1.e013814.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209595"},{"key":"2026012707402071000_14.1.e013814.28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2026012707402071000_14.1.e013814.29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026012707402071000_14.1.e013814.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"key":"2026012707402071000_14.1.e013814.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116"},{"key":"2026012707402071000_14.1.e013814.32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-061909-093311"},{"key":"2026012707402071000_14.1.e013814.33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1016-8478(23)17417-6","article-title":"SUMOylation code in cancer development and metastasis","volume":"22","author":"Kim","year":"2006","journal-title":"Mol Cells"},{"key":"2026012707402071000_14.1.e013814.34","doi-asserted-by":"crossref","first-page":"1376633","DOI":"10.3389\/fonc.2024.1376633","article-title":"PIAS family in cancer: from basic mechanisms to clinical applications","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"2026012707402071000_14.1.e013814.35","doi-asserted-by":"publisher","DOI":"10.3390\/biom2030376"},{"key":"2026012707402071000_14.1.e013814.36","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170024","article-title":"SUMOylation pathway alteration coupled with downregulation of SUMO E2 enzyme at mucosal epithelium modulates inflammation in inflammatory bowel disease","volume":"7","author":"Mustfa","year":"2017","journal-title":"Open Biol"},{"key":"2026012707402071000_14.1.e013814.37","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2017.9"},{"key":"2026012707402071000_14.1.e013814.38","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.24.10584-10592.2004"},{"key":"2026012707402071000_14.1.e013814.39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2016.04.009","article-title":"Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets","volume":"176","author":"Yadav","year":"2016","journal-title":"Transl Res"},{"key":"2026012707402071000_14.1.e013814.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-022-00343-8","article-title":"Bi-allelic ATG4D variants are associated with a neurodevelopmental disorder characterized by speech and motor impairment","volume":"8","author":"Morimoto","year":"2023","journal-title":"NPJ Genom Med"},{"key":"2026012707402071000_14.1.e013814.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01496-w","article-title":"Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective","volume":"9","author":"Fratta","year":"2023","journal-title":"Cell Death Discov"},{"key":"2026012707402071000_14.1.e013814.42","first-page":"4100","article-title":"A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells","volume":"59","author":"Lucas","year":"1999","journal-title":"Cancer Res"},{"key":"2026012707402071000_14.1.e013814.43","first-page":"2789","article-title":"Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases","volume":"25","author":"Korabiowska","year":"2005","journal-title":"Anticancer Res"},{"key":"2026012707402071000_14.1.e013814.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00793.x"},{"key":"2026012707402071000_14.1.e013814.45","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.1304"},{"key":"2026012707402071000_14.1.e013814.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110996109"},{"key":"2026012707402071000_14.1.e013814.47","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s10620-009-1032-9","article-title":"Effects of the gastrin-releasing peptide antagonist RC-3095 in a rat model of ulcerative colitis","volume":"55","author":"Damin","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2026012707402071000_14.1.e013814.48","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200008000-00012"},{"key":"2026012707402071000_14.1.e013814.49","first-page":"707","article-title":"Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma","volume":"38","author":"Marrone","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"2026012707402071000_14.1.e013814.50","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041034","article-title":"Biological Role and Aberrant Overexpression of Syntenin-1 in Cancer: Potential Role as a Biomarker and Therapeutic Target","volume":"11","author":"Pintor-Romero","year":"2023","journal-title":"Biomedicines"},{"key":"2026012707402071000_14.1.e013814.51","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223284"},{"key":"2026012707402071000_14.1.e013814.52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.autrev.2015.01.015","article-title":"Emerging clinical phenotypes associated with anti-cytokine autoantibodies","volume":"14","author":"Vincent","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2026012707402071000_14.1.e013814.53","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11072026","article-title":"Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years)","volume":"11","author":"Reschke","year":"2022","journal-title":"J Clin Med"},{"key":"2026012707402071000_14.1.e013814.54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122902","article-title":"Identifying High-Risk Tumors within AJCC Stage IB-III Melanomas Using a Seven-Marker Immunohistochemical Signature","volume":"13","author":"Reschke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026012707402071000_14.1.e013814.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115372"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:40:33Z","timestamp":1769528433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013814"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013814","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}